Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors
Altimmune (Nasdaq: ALT) has appointed Teri Lawver and Jerry Durso to its Board of Directors as the company advances into late-stage clinical development for pemvidutide and prepares for transition to a pre-commercial organization.
Lawver brings nearly 30 years of healthcare experience, most recently serving as Chief Commercial Officer at Dexcom where she led the launch of the industry's first over-the-counter glucose biosensor. Previously, she spent 20 years at Johnson & Johnson in senior leadership roles, including global commercial responsibility for Janssen's $16 billion immunology portfolio.
Durso has over 30 years of leadership experience, most recently as CEO of Intercept Pharmaceuticals where he built a successful rare liver disease franchise and led the company through its acquisition by Alfasigma. He previously spent over 20 years at Sanofi in various senior positions.
Both executives will help guide Altimmune's strategic vision to develop and commercialize pemvidutide, which has shown promising effects on liver defatting, weight loss, and serum lipid improvements.
Altimmune (Nasdaq: ALT) ha nominato Teri Lawver e Jerry Durso nel suo Consiglio di Amministrazione mentre l'azienda avanza verso lo sviluppo clinico avanzato per il pemvidutide e si prepara alla transizione verso un'organizzazione pre-commerciale.
Lawver porta con sé quasi 30 anni di esperienza nel settore sanitario, avendo recentemente ricoperto il ruolo di Chief Commercial Officer presso Dexcom, dove ha guidato il lancio del primo biosensore per il glucosio da banco del settore. In precedenza, ha trascorso 20 anni in Johnson & Johnson in ruoli di leadership senior, inclusa la responsabilità commerciale globale per il portafoglio di immunologia da 16 miliardi di dollari di Janssen.
Durso ha oltre 30 anni di esperienza nella leadership, recentemente come CEO di Intercept Pharmaceuticals, dove ha costruito una franchigia di successo per le malattie rare del fegato e ha guidato l'azienda attraverso l'acquisizione da parte di Alfasigma. In precedenza, ha trascorso oltre 20 anni in Sanofi in varie posizioni senior.
Entrambi i dirigenti aiuteranno a guidare la visione strategica di Altimmune per sviluppare e commercializzare il pemvidutide, che ha mostrato effetti promettenti sulla riduzione del grasso epatico, sulla perdita di peso e sui miglioramenti dei lipidi sierici.
Altimmune (Nasdaq: ALT) ha nombrado a Teri Lawver y Jerry Durso en su Junta Directiva mientras la empresa avanza hacia el desarrollo clínico de última etapa para el pemvidutide y se prepara para la transición a una organización precomercial.
Lawver aporta casi 30 años de experiencia en el sector de la salud, habiendo servido más recientemente como Directora Comercial en Dexcom, donde lideró el lanzamiento del primer biosensor de glucosa de venta libre en la industria. Anteriormente, pasó 20 años en Johnson & Johnson en roles de liderazgo senior, incluyendo la responsabilidad comercial global del portafolio de inmunología de Janssen de 16 mil millones de dólares.
Durso tiene más de 30 años de experiencia en liderazgo, más recientemente como CEO de Intercept Pharmaceuticals, donde construyó una exitosa franquicia de enfermedades hepáticas raras y guió a la empresa a través de su adquisición por Alfasigma. Anteriormente, pasó más de 20 años en Sanofi en diversas posiciones senior.
Ambos ejecutivos ayudarán a guiar la visión estratégica de Altimmune para desarrollar y comercializar el pemvidutide, que ha mostrado efectos prometedores en la reducción de grasa hepática, la pérdida de peso y las mejoras en los lípidos séricos.
Altimmune (Nasdaq: ALT)는 Teri Lawver와 Jerry Durso를 이사회에 임명하면서 회사가 펨비듀타이드의 후기 임상 개발로 나아가고 있으며 상업화 전 조직으로의 전환을 준비하고 있습니다.
Lawver는 최근 Dexcom에서 최고 상업 책임자로 재직하며 업계 최초의 일반의약품 글루코스 바이오센서를 출시한 경험을 포함해 거의 30년의 의료 경험을 가지고 있습니다. 이전에는 Johnson & Johnson에서 20년 이상 고위 리더십 역할을 수행하며 Janssen의 160억 달러 규모의 면역학 포트폴리오에 대한 글로벌 상업적 책임을 맡았습니다.
Durso는 30년 이상의 리더십 경험을 가지고 있으며, 최근 Intercept Pharmaceuticals의 CEO로서 성공적인 희귀 간 질환 프랜차이즈를 구축하고 Alfasigma에 인수되는 과정을 이끌었습니다. 이전에는 Sanofi에서 20년 이상 다양한 고위직에서 근무했습니다.
두 임원은 Altimmune의 전략적 비전을 안내하여 펨비듀타이드를 개발하고 상업화하는 데 도움을 줄 것입니다. 이는 간 지방 감소, 체중 감소 및 혈청 지질 개선에 유망한 효과를 보여주었습니다.
Altimmune (Nasdaq: ALT) a nommé Teri Lawver et Jerry Durso à son conseil d'administration alors que l'entreprise progresse vers le développement clinique avancé du pemvidutide et se prépare à une transition vers une organisation pré-commerciale.
Lawver apporte près de 30 ans d'expérience dans le secteur de la santé, ayant récemment occupé le poste de Directrice Commerciale chez Dexcom, où elle a dirigé le lancement du premier biosenseur de glucose en vente libre de l'industrie. Auparavant, elle a passé 20 ans chez Johnson & Johnson dans des rôles de direction senior, y compris la responsabilité commerciale mondiale pour le portefeuille d'immunologie de Janssen de 16 milliards de dollars.
Durso a plus de 30 ans d'expérience en leadership, ayant été récemment PDG d'Intercept Pharmaceuticals, où il a construit une franchise réussie pour les maladies hépatiques rares et a dirigé l'entreprise à travers son acquisition par Alfasigma. Auparavant, il a passé plus de 20 ans chez Sanofi à divers postes de direction.
Les deux dirigeants aideront à guider la vision stratégique d'Altimmune pour développer et commercialiser le pemvidutide, qui a montré des effets prometteurs sur la réduction des graisses hépatiques, la perte de poids et les améliorations des lipides sériques.
Altimmune (Nasdaq: ALT) hat Teri Lawver und Jerry Durso in seinen Vorstand berufen, während das Unternehmen in die späte klinische Entwicklung für Pemvidutide eintritt und sich auf den Übergang zu einer prä-kommerziellen Organisation vorbereitet.
Lawver bringt fast 30 Jahre Erfahrung im Gesundheitswesen mit, zuletzt als Chief Commercial Officer bei Dexcom, wo sie die Einführung des ersten rezeptfreien Glukose-Biosensors der Branche leitete. Zuvor war sie 20 Jahre lang in leitenden Positionen bei Johnson & Johnson tätig, darunter die globale kommerzielle Verantwortung für das Immunologie-Portfolio von Janssen in Höhe von 16 Milliarden US-Dollar.
Durso hat über 30 Jahre Führungserfahrung und war zuletzt CEO von Intercept Pharmaceuticals, wo er eine erfolgreiche Franchise für seltene Lebererkrankungen aufbaute und das Unternehmen durch die Übernahme durch Alfasigma führte. Zuvor war er über 20 Jahre in verschiedenen Führungspositionen bei Sanofi tätig.
Beide Führungskräfte werden helfen, die strategische Vision von Altimmune zu leiten, um Pemvidutide zu entwickeln und zu kommerzialisieren, das vielversprechende Effekte auf die Leberfettreduktion, Gewichtsverlust und Serumlipidverbesserungen gezeigt hat.
- Addition of two seasoned executives with extensive commercialization experience
- Strategic preparation for late-stage clinical development and potential commercial launch
- Lawver brings expertise in cardiovascular, metabolic diseases, and global commercial strategy
- Durso brings specific experience in liver disease commercialization
- Both executives have overseen successful product launches and late-stage development
- Pemvidutide shows promising effects on liver defatting, weight loss, and lipid improvements
- None.
Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascular & Metabolism Portfolios over her 20-year career
Mr. Durso led biopharmaceutical company focused on liver disease as former CEO of Intercept Pharmaceuticals, previously oversaw multiple blockbuster franchises including cardiovascular and diabetes during 22-year tenure at Sanofi
GAITHERSBURG, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the expansion of its Board of Directors with the appointments of Teri Lawver and Jerry Durso.
“We are thrilled to welcome Teri and Jerry to our Board as we move into late-stage clinical development for pemvidutide and begin preparing for the transition to a pre-commercial-stage organization,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “Teri’s deep expertise leading large organizations and global portfolios in cardiovascular and metabolic diseases and other therapeutic areas coupled with Jerry’s extensive leadership experience in biopharmaceutical commercialization and corporate strategy, particularly in liver disease, will be invaluable as we continue advancing the pemvidutide franchise. Teri and Jerry have overseen late-stage development, approvals and launches of multiple products during their distinguished careers. The breadth and depth of their executive and commercialization expertise will enhance our talented Board and will help guide the continued execution of our strategic vision to develop and commercialize pemvidutide.”
Teri Lawver is an accomplished healthcare executive with nearly 30 years of experience across the pharmaceutical, medical device and consumer health technology sectors. She most recently served as Executive Vice President and Chief Commercial Officer at Dexcom (Nasdaq: DXCM), where she led global commercial strategy and operations, including the launch of the industry’s first over-the-counter glucose biosensor. Prior to Dexcom, she spent two decades at Johnson & Johnson in a series of senior leadership roles spanning strategy, commercialization and executive management, including serving as Global Vice President for Janssen’s Cardiovascular & Metabolism therapeutic area and subsequently Worldwide Vice President for the Immunology business at Janssen Pharmaceuticals, where she had global commercial responsibility for Janssen’s
Ms. Lawver stated, “It is an honor to join Altimmune’s Board at such an exciting time in the Company’s evolution. Pemvidutide has shown what I believe to be compelling direct liver effects plus robust weight loss with significant lipid reductions and preservation of lean muscle mass. I am excited to work alongside the other Board members and the leadership team to continue advancing pemvidutide toward a potential commercial launch.”
Jerry Durso brings over 30 years of results-oriented leadership experience in the life sciences industry, with expertise in corporate and commercial strategy and business operations. He most recently served as Chief Executive Officer and a member of the Board of Directors of Intercept Pharmaceuticals, where he built a successful rare liver disease franchise and ultimately led the company through its successful acquisition by Alfasigma. Prior to his time at Intercept, Mr. Durso spent over two decades at Sanofi, where he held multiple senior leadership positions, including Chief Commercial Officer of the Company’s Global Diabetes Division, Chief Commercial Officer of its U.S. Pharmaceuticals business and Head of its U.S. Cardiovascular and Specialized Therapeutic Business Units. He holds a BBA in marketing from the University of Notre Dame.
Mr. Durso added, “Pemvidutide is a very exciting product candidate that not only drives significant liver defatting, but also has been shown to promote clinically meaningful weight loss and improvements in serum lipids, potentially offering a benefit across a range of liver and metabolic diseases. I look forward to contributing my late-stage clinical and commercial experience to work with the Board and the management team to help bring pemvidutide to patients in need.”
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
This press release was published by a CLEAR® Verified individual.
FAQ
What executive appointments did Altimmune (ALT) announce on February 25, 2025?
What is Teri Lawver's background before joining Altimmune's board?
What experience does Jerry Durso bring to Altimmune's board?
Why is Altimmune (ALT) expanding its board with these specific executives?
What therapeutic areas does Altimmune's pemvidutide target?
